description
General Background The ω 3 polyunsaturated fatty acids are known to be essential for proper neuronal and immune function. Deficiencies in these important fatty acids are associated with mental dysfunction, cardiovascular disorders, cancer and other diseases. A new class of aspirin-triggered lipid based anti-inflammatory mediators derived from the ω 3 fatty acids : 5Z8Z11Z14Z17Z-EICOSAPENTAENOATE and : CPD-10244 have recently been identified. They have been termed resolvins (resolution phase interaction products) and those derived from DHA are termed the D-series resolvins . These endogenous mediators have a wide distribution in leukocytes, brain and glial cells. : CPD-524 "Aspirin" has well known anti-inflammatory, antipyretic functions and anticoagulant functions. It is often prescribed long-term, at low doses, to help prevent heart attacks, strokes, and blood clot formation in high risk patients. Aspirin may also prevent the occurrence of certain types of cancer. Aspirin exerts its actions by the inhibition of both : HS01815-MONOMER "COX-1" and : HS01115-MONOMER "COX-2" which has a negative effect on prostaglandin synthesis. It irreversibly acetylates COX-2 which loses the ability to generate prostaglandin intermediates. However, COX-2 retains oxygenase activity which results in the production of various types of anti-inflammatory mediators. About this Pathway : CPD-524 "Aspirin" acetylated COX-2 converts unesterified : CPD-10244 released from phosphatidylethanolamine to the 17R- series resolvins via 17R-hydroperoxy-DHA . This has been observed in human microvascular endothelial cells. 5-lipoxygenation inserts hydroperoxy at either the 4 or 7 position resulting in the formation of two intermediates. These are rapidly converted to the 4,5 epoxide and 7,8 epoxide respectively giving rise to the17R series resolvins . During ischemic conditions like stroke or coronary thrombosis, there is leukocyte infiltration and release of pro-inflammatory cytokines which contribute to tissue damage. Ischemia also causes release of DHA from membrane phospholipids. Aspirin mediated biosynthesis of the 17R series resolvins can inhibit both leukocyte infiltration and cytokine expression . There is also a de novo 17S resolvin synthesis pathway that occurs in the absence of aspirin, see : PWY66-397

external resources
NCBI:782385
BIOCYC:HUMAN_PWY66-395
PUBMED:15726828
PUBMED:12590139

genes
ALOX5 , PTGS2 ,